

Aimmune Therapeutics, Inc.

Form 4

March 31, 2016

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Longitude Capital Partners II, LLC

(Last) (First) (Middle)

800 EL CAMINO REAL, SUITE
220

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

Aimmune Therapeutics, Inc. [AIMT]

3. Date of Earliest Transaction
(Month/Day/Year)

03/29/2016

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
____X____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|----------------------------------|--------------------------------------|--|--------------------------------|---|--------|---|--|---|---|
| | | | Code | V | Amount | (A) or (D) Price | | | |
| Common Stock, \$0.0001 par value | 03/29/2016 | | P | | 33,064 | A \$ 13.4986 ⁽¹⁾ | 7,467,694 | I | By Longitude Venture Partners II, L.P. ⁽²⁾ |
| Common Stock, \$0.0001 par value | 03/29/2016 | | P | | 45,440 | A \$ 14.1465 ⁽³⁾ | 7,513,134 | I | By Longitude Venture Partners II, L.P. ⁽²⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 3 and 4) |
|---|--|---|---|--------------------------------------|--|--|---|---|--|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Longitude Capital Partners II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 | | X | | |
| Longitude Venture Partners II, L.P. 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 | | X | | |
| Tammenoms Bakker Juliet 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 | | X | | |
| ENRIGHT PATRICK G 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025 | | X | | |

Signatures

LONGITUDE CAPITAL PARTNERS II, LLC, a Delaware limited liability company, By: /s/
Patrick G. Enright, Managing Member

03/31/2016

__Signature of Reporting Person

Date

LONGITUDE VENTURE PARTNERS II, L.P., By: Longitude Capital Partners II, LLC, a
Delaware limited liability company, Its General Partner, By: /s/ Patrick G. Enright, Managing
Member

03/31/2016

Edgar Filing: Aimmune Therapeutics, Inc. - Form 4

__Signature of Reporting Person

Date

/s/ Juliet Tammenoms Bakker

03/31/2016

__Signature of Reporting Person

Date

/s/ Patrick G. Enright

03/31/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from \$12.90 to \$13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

(2) This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.

(3) Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from \$13.90 to \$14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.